rybrevant Archives - GO2 for Lung Cancer

FDA Approves New Combination Therapy for People with Advanced EGFR+ NSCLC

Bethany Johnson (GO2 for Lung Cancer)2024-09-20T10:29:57-05:00September 20th, 2024|Hot Topics, News, Science and Research|

On September 19, 2024, the U.S. Food and Drug Administration (FDA) issued a new approval for the targeted therapy drug Rybrevant (amivantamab-vmjw) in combination with the existing combination chemotherapy treatment, Paraplatin (carboplatin) + Alimta (pemetrexed). The FDA approved this [...]

FDA Approves Rybrevant as First Targeted Treatment for Patients with NSCLC with EGFR Exon 20 Insertion Mutations

On May 21st, 2021, the Food and Drug Administration (FDA) approved Rybrevant (amivantamab-vmjw) for treatment of advanced non-small cell lung cancer (NSCLC) with a change in EGFR called exon 20 insertion. The FDA based their approval on the results of [...]